

Date: June 11, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292, ISIN: INE013P01021 Scrip Code: 975645, ISIN: 1NE013P07028	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ONESOURCE
---	--

Dear Sir/Madam,

Subject: Update

This is in continuation to our earlier intimation dated June 10, 2025, regarding the proposed subscription to the equity shares of Xbrane Biopharma AB, Sweden.

In this regard, please find enclosed the press release titled:

“OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets.”

You are requested to kindly take the above information on record.

For OneSource Specialty Pharma Limited

Trisha A
Compliance Officer and Company Secretary
Membership Number: A47635

OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets

Bangalore, India, and Stockholm, Sweden, June 11, 2025 — OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), a multi-modality specialty pharma pure-play CDMO, and Xbrane Biopharma AB (“Nasdaq” ticker XBRANE), a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane’s biosimilar portfolio.

Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch.

As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource’s state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbrane’s global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbrane’s latest funding round, reinforcing the long-term alignment between the two companies.

Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, said: *“The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”*

Martin Åmark, CEO of Xbrane Biopharma, added: *“Our partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.”*

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com or contact:

<u>Institutional Investors</u> Anurag Bhagania CFO Tejaswani Fotedar Email: investor-relations@onesourcecdmo.com	<u>Corporate Communication</u> Pallavi Panchmatia: +91 8951939181 Abhilash Mukherjee: +91 89044 28907 Email: corpcomm@onesourcecdmo.com <u>PR Consultancy</u> Adfactors PR Janhavi Bellare: +91 93228 54508 Email: Janhavi.bellare@adfactorspr.com Syed Talal: +91 99876 19679 Email: syed.talal@adfactorspr.com
---	--

About Xbrane Biopharma

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com or contact:

Martin Åmark, CEO martin.amark@xbrane.com	Jane Benyamin, CFO/IR jane.benyamin@xbrane.com
--	--